A book lies open on a surface and a compass, planet, molecule, cell, test tube, and paintbrush hover above the pages.

The most truthful science stories don’t ignore, but embrace, nuance.

credit: istock/Alena Butusava

Making a mess of the tidy narrative

Accuracy doesn’t only apply to isolated facts, but to the overall picture they paint.  
Sarah Anderson, PhD
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

When I studied science journalism at Northwestern University, my professor Patti Wolter shared a powerful anecdote about popcorn. During her days as a magazine editor, a writer wanted to critique the two-hour wait times for Chicago’s famous Garrett Popcorn. It sounded like a fun, cheeky story lamenting the years lost to its signature caramel and cheddar combo. 

But in probing further, my professor discovered that the blanket statement about two-hour waits wasn’t the whole truth: The waits are only that long at the tourist-filled Magnificent Mile location on the weekends. While it would have made for a much cleaner narrative to omit that inconvenient detail, it wouldn’t have been fair. Checking a story for accuracy doesn’t only mean making sure each individual fact is correct, but that the premise behind them considers all of the available information. 

Scientists appreciate a tidy narrative too. A leads to B leads to C. X causes disease, and getting rid of X treats it. By the same token, researchers are susceptible to overlooking information that doesn’t fit within that storyline. This phenomenon is no more apparent than in the pursuit of treatments for Alzheimer’s disease, which affects about 10 percent of Americans age 65 and older. The leading hypothesis driving the development of drugs for Alzheimer’s disease is neat and logical: Clumps of amyloid protein in the brain strangle neurons, resulting in neurodegeneration. Breaking up those clumps will hopefully treat the disease. 

However, as amyloid-targeting treatments repeatedly failed in the clinic and new mechanisms behind Alzheimer’s disease emerged, some researchers suspected that amyloid clumps may be a biomarker of the disease rather than the cause. “In that case, targeting amyloid would no more revive dead neurons than removing headstones would resurrect bodies in a cemetery,” wrote Sharon Begley in a groundbreaking exposé. Begley explained how scientists challenging the amyloid hypothesis were ignored and presented the very real possibility that decades of tunnel-visioned Alzheimer’s disease research delayed treatment development and cost lives.

While signs of research misconduct in a landmark amyloid study came to light last summer, most research on amyloid arose from good and honest intentions. Researchers performed well-controlled experiments and reported the data accurately. The facts may have been facts, but they excluded the larger clinical context like Garrett Popcorn on a Tuesday, weaving a tidy tale in papers and presentations that has yet to yield meaningful results for patients.

Scientists and journalists alike should not only fact check, but fair check their work by interrogating their blind spots, seeking the whole picture, and embracing nuance. It might make our narratives messier, but it will also make them more truthful, and that’s important, whether the subject is something as trivial as popcorn or as serious as Alzheimer’s disease. 

About the Author

  • Sarah Anderson, PhD
    Sarah Anderson joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in chemistry and master’s degree in science journalism from Northwestern University and served as managing editor of “Science Unsealed.”

Related Topics

Published In

February 2023 Front Cover
Volume 19 - Issue 2 | February 2023

February 2023

February 2023 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Blue sinusoidal pulse lines are shown in light blue against a dark blue background, representing a heartbeat signal.

Getting to the heart of drug safety testing

High throughput optical scanning enhances cardiac ion channel analysis for safer drug development.
A blue and orange double-helix representing DNA is undergoing transcription with a large orange shape representing RNA polymerase against a blue background

Harnessing CRISPR-Cas9: Knocking out genes in myeloid cells

Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.
A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue